Form 4: Genprex Chief Medical Officer Disposes of Shares for Tax Obligations

Genprex's Chief Medical Officer, Mark Stanley Berger, disposed of 4,500 common shares to satisfy tax withholding obligations related to the vesting of Restricted Stock Units.

Summary

• Mark Stanley Berger, the Chief Medical Officer of Genprex, Inc. (GNPX), reported a transaction on June 30, 2025.
• The transaction involved the disposition of 4,500 shares of Common Stock at a price of $0.2279 per share.
• These shares were withheld to cover tax withholding obligations associated with the vesting of Restricted Stock Units (RSUs).
• The RSUs were previously granted under the Genprex, Inc. 2018 Equity Incentive Plan.
• Following this transaction, Mark Stanley Berger beneficially owns 17,971 shares of Common Stock directly.

Sentiment

Score: 5

Explanation: The document reports a routine insider transaction for tax withholding purposes, which is a neutral event and does not indicate positive or negative sentiment regarding the company's performance or outlook.

Future Outlook

The document does not contain any forward-looking statements or guidance.

Industry Context

This Form 4 filing is a routine disclosure of an insider transaction, specifically the disposition of shares to cover tax liabilities upon RSU vesting. Such transactions are common across all industries, including the biotechnology and pharmaceutical sectors where equity compensation is a standard practice.

Stakeholder Impact

• Shareholders: The transaction represents a minor reduction in the Chief Medical Officer's direct beneficial ownership due to tax obligations, which is a routine event and generally has minimal direct impact on other shareholders.

Key Dates

Keywords

Genprex, GNPX, Mark Stanley Berger, Chief Medical Officer, SEC Form 4, Insider Transaction, Restricted Stock Units, RSU Vesting, Tax Withholding, Equity Incentive Plan